20:12 , Feb 9, 2018 |  BC Week In Review  |  Company News

Advanced Proteome, ImmunoBiochem to develop ADCs for TNBC

Advanced Proteome Therapeutics Corp. (TSX-V:APC; FSE:0E8) and ImmunoBiochem Corp. (Toronto, Ontario) will evaluate combining an undisclosed antibody from ImmunoBiochem with Advanced Proteome's site-selective conjugation technology to develop antibody-drug conjugates (ADCs) to treat triple-negative breast cancer...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Company News

University of Toronto, Advanced Proteome Therapeutics deal

The university’s Toronto Recombinant Antibody Centre (TRAC) granted Advanced Proteome an exclusive option to license preclinical oncology antibody candidates against an undisclosed target to develop antibody-drug conjugates (ADCs) using Advanced Proteome’s protein conjugation technology. The...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Company News

Advanced Proteome Therapeutics, Wilex deal

Advanced Proteome and Wilex’s Heidelberg Pharma GmbH subsidiary partnered to create antibody-drug conjugates (ADCs) to treat cancer. Heidelberg will contribute its Antibody Targeted Amanitin Conjugates (ATACs) technology, and Advanced Proteome will provide its site-specific protein...
07:00 , May 30, 2016 |  BC Week In Review  |  Financial News

Advanced Proteome Therapeutics completes private placement of units

Advanced Proteome Therapeutics Corp. (TSX-V:APC; FSE:0E8), Boston, Mass.   Business: Drug delivery   Date completed: 2016-05-19   Type: Private placement of units   Raised: C$285,150 ($217,170)   Units: 5.7 million   Price: C$0.05 (unit)   Shares after offering: 118.6 million   Placement agent:...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Financial News

Advanced Proteome Therapeutics proposes private placement of units

Advanced Proteome Therapeutics Corp. (TSX-V:APC; FSE:0E8), Boston, Mass.   Business: Drug delivery   Date announced: 2016-04-18   Type: Private placement of units   To be raised: Up to C$300,000 ($231,930)   Units: 6 million   Price: C$0.05   Shares outstanding prior: 112.9...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

Advanced Proteome Therapeutics preclinical data

In a mouse model of breast cancer, APC 101 reduced metastases to the lungs. APC 101 is an undisclosed human protein targeting an undisclosed biomarker on the cell surface of certain cancer cells. Advanced Proteome...